Search
01/01/2025
Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study
Hernández, G, Martin, M, Alonso, S, Romero, I, Salvado, N, Farrés, M, Osuna, C, Bustínduy, M, de Araníbar, JG, Manresa, M, Velasco, M, Ferrer, A, Riesco, M, Genao, D, Ruíz-Villaverde, R, Boquete, L, Martínez, C, Rull, E, Descalzo, MA. Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.05.022. PMID:38876209. IF:(Q/D).
01/01/2025
Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study
Hernández, GC, Martín, MA, Alonso, SA, Romero, IB, Salvado, NE, Farrés, MF, Osuna, CG, Bustínduy, MG, de Aranibar, JGL, Manresa, MJ, Velasco, ML, Ferrer, AL, Riesco, MR, Genao, DR, Ruíz-Villaverde, R, Boquete, LS, Martínez, CS, Rull, EV, Descalzo, MA. Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.10.009. PMID:. IF:(Q/D).
01/01/2025
Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy
Mateu-Arrom, L, Puig, L. Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy. Psoriasis-Targets And Therapy. 2025; 15DOI:10.2147/PTT.S510141. PMID:40237012. IF:(Q/D).
31/12/2024
Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Girolomoni, G, Feldman, SR, Egeberg, A, Puig, L, Jung, J, Jung, H, Lee, Y. Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). JOURNAL OF DERMATOLOGICAL TREATMENT. 2024; 35(1)DOI:10.1080/09546634.2024.2434091. PMID:39626886. IF:3.900(Q1/2D).
05/12/2024
Safety in patients with latent tuberculosis who received concomitant anti-tuberculosis medications: analysis of 11 studies of guselkumab in psoriatic disease
Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londono, A, Lebwohl, M, Nash, P. Safety in patients with latent tuberculosis who received concomitant anti-tuberculosis medications: analysis of 11 studies of guselkumab in psoriatic disease. BRITISH JOURNAL OF DERMATOLOGY. 2024; 191DOI:10.1093/bjd/ljae360.098. PMID:. IF:9.600(Q1/1D).
05/12/2024
Effectiveness of biologics in clinical practice: Month 12 absolute psoriasis area and severity index outcomes from an international observational Psoriasis Study of Health Outcomes
Maul, JT, Bonnekoh, B, Puig, L, McKenzie, R, Lampropoulou, A, Martimianaki, G, Fotiou, K, Pinter, A, Akiror, C. Effectiveness of biologics in clinical practice: Month 12 absolute psoriasis area and severity index outcomes from an international observational Psoriasis Study of Health Outcomes. BRITISH JOURNAL OF DERMATOLOGY. 2024; 191DOI:10.1093/bjd/ljae360.093. PMID:. IF:9.600(Q1/1D).